Metformin improved vascular smooth muscle function and HbA1c, and lowered insulin dose in type 1 diabetes children, but had no effect on other cardiovascular risk factors (such as fat mass, lipid profile and CRP). The gene discussed is INS; the disease is type 1 diabetes mellitus.